

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)



(10) International Publication Number
WO 2021/222363 A1

(51) International Patent Classification:

C07D 401/04 (2006.01) C07D 491/056 (2006.01)
C07D 401/14 (2006.01) C07D 513/04 (2006.01)
C07D 403/04 (2006.01) A61P 3/00 (2006.01)
C07D 405/14 (2006.01) A61P 7/00 (2006.01)
C07D 413/14 (2006.01) A61P 13/00 (2006.01)
C07D 417/04 (2006.01) A61P 35/00 (2006.01)
C07D 417/14 (2006.01) A61K 31/517 (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:

PCT/US2021/029574

(22) International Filing Date:

28 April 2021 (28.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/016,891 28 April 2020 (28.04.2020) US
63/127,774 18 December 2020 (18.12.2020) US

(71) Applicant: GLOBAL BLOOD THERAPEUTICS, INC.


[US/US]; 181 Oyster Point Blvd., South San Francisco, California 94080 (US).

(72) Inventors: **XU, Qing**; c/o Global Blood Therapeutics, Inc., 181 Oyster Point Blvd., South San Francisco, California 94080 (US). **ALT, Carsten**; c/o Global Blood Therapeutics, Inc., 181 Oyster Point Blvd., South San Francisco, California 94080 (US). **LI, Zhe**; c/o Global Blood Therapeutics, Inc., 181 Oyster Point Blvd., South San Francisco, California 94080 (US). **NILAR, Shahul**; c/o Global Blood Therapeutics, Inc., 181 Oyster Point Blvd., South San Francisco, California 94080 (US). **RADEMACHER, Peter Michael**; c/o Global Blood Therapeutics, Inc., 181 Oyster Point Blvd., South San Francisco, California 94080 (US). **YEE, Calvin Wesley**; c/o Global Blood Therapeutics, Inc., 181 Oyster Point Blvd., South San Francisco, California 94080 (US).


(74) Agent: **SANDERS, Marisa B.** et al.; Alston & Bird LLP, One South at The Plaza, 101 South Tryon Street, Suite 4000, Charlotte, North Carolina 28280-4000 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS



(I)



(I')

(57) Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.



WO 2021/222363 A1

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*